News articles about Supernus Pharmaceuticals (NASDAQ:SUPN) have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Supernus Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.726508265019 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Supernus Pharmaceuticals (SUPN) Raised to Buy at Janney Montgomery Scott (americanbankingnews.com)
- Benzinga’s Top Upgrades, Downgrades For December 4, 2017 – Benzinga (benzinga.com)
- Supernus Pharmaceuticals (SUPN) Downgraded to “Hold” at ValuEngine (americanbankingnews.com)
- Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Post Quarterly Sales of $88.02 Million (americanbankingnews.com)
- Supernus Pharmaceuticals, Inc. (SUPN) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
SUPN has been the subject of several recent research reports. Cowen restated a “buy” rating and set a $50.00 price target on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Jefferies Group reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. FBR & Co began coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $53.00 price objective for the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $49.60.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at $37.10 on Wednesday. The firm has a market cap of $1,906.95, a PE ratio of 35.09, a P/E/G ratio of 1.57 and a beta of 1.19. Supernus Pharmaceuticals has a 1-year low of $21.60 and a 1-year high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals’s revenue was up 41.5% compared to the same quarter last year. research analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.
In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the sale, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $623,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The disclosure for this sale can be found here. Insiders sold a total of 150,000 shares of company stock valued at $7,055,350 over the last three months. 6.70% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/12/06/supernus-pharmaceuticals-supn-earning-somewhat-positive-press-coverage-accern-reports.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.